Stocks plunge to 52-week lows: Earnings and valuation
Nuvation Bio, Innoviva, Globus Medical, and Somnigroup International stocks hit 52-week lows. Despite declines, some are undervalued or show upside, while earnings results were mixed.
Nuvation Bio Inc’s stock hit a 52-week low at $3.91, marking a 55% year-to-date decline and a 14.56% drop over the past year. Despite ongoing losses, analysts remain optimistic, setting price targets between $7 and $21. The company’s Q3 revenue of $44.95 million exceeded expectations, driven by strong sales of its lead cancer drug, though it reported a loss of $0.12 per share. Innoviva Inc’s stock also reached a 52-week low at $18.60, down 14.93% year-over-year. The stock is considered undervalued, trading at low P/E and PEG ratios, with strong free cash flow and a high financial health rating. Globus Medical’s stock touched a 52-week low at $70.39, down 15.55% year-over-year. While Q3 revenue missed expectations, earnings per share were slightly better than forecast. Somnigroup International’s stock fell to a 52-week low of $60.07, down 29.73% over the year. Despite missing Q3 forecasts, the company reported record net sales and progress from a recent acquisition, though the stock is currently overvalued by Fair Value metrics.